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Background. Retro-orbital radiotherapy in patients with Graves’ disease is a technique widely used as initial local therapy and for
patients refractory to other treatments. Advances in radiotherapy have improved dosimetric parameters minimizing damage to
surrounding structures.
Objectives. Compare with the standard technique of irradiation, new technologies used in radiotherapy, such as IMRT.
Methods. We present a case of a 50-years old woman with bilateral symptomatic Graves’ disease. The patient was referred
after ineffective treatment (corticosteroids). An individual 3DCRT (using two laterals ﬁelds) and IMRT (6 ﬁelds, adding oblique
posterior and coronal) was created. Radiation dose was 20Gy in 10 fractions. Conformity index (CI), homogeneity index (HI) and
other dosimetric parameters of organs at risk (globes, lenses, pituitary gland and optic chiasm) were compared.
Results. Similarly CI was generated by IMRT and 3DRTC (1.3 vs 1.5). IH was described <2.5 for both plans (1.05 vs 1.06 respectively).
IMRT gave rise to better dose sparing to surrounding structures as compared with 3DRTC (mean doses, on Gy): lenses (1.77 vs
3.14 on right, and 2.13 vs 3.57 on left), globes (8.31 vs 9.89 on right, and 7.85 vs 9.87 on left), pituitary gland (0.69 vs 1.41) and optic
chiasm (0.82 vs 2.38).
Conclusions. Retro-orbital irradiation is an effective and well tolerated local therapy for Graves’ disease. As compared with 3DCRT,
IMRT have similar target coverage and show better dose sparing to organ as risk. Its routine use must be supported by larger
series and longer follow-up.
http://dx.doi.org/10.1016/j.rpor.2013.03.375
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Introduction. Patients receiving craniospinal irradiation are at a signiﬁcant risk to develop late sequelae due to the close proximity
of radiosensitive organs to the target volume. The feasibility of using VMAT to reduce the organs-at-risk dose was evaluated.
Purpose. To describe our procedure of VMAT pediatric craniospinal irradiation (CSI).
Method. The patient is a 4 year’s old child diagnosed in 2009 of Leukaemia with brain’s inﬁltration. Fourth relapse in SNC occurred
in 2012 in treatment with chemotherapy. The patient was immobilized by eXaFrame (Anatomical-Geometry) and treatment
design was performed in Pinnacle v9.2. (Philips). An auxiliary contour (CPE) is created as the external contour minus 12mm.
The upper target is created as brain minus CPE plus part of the spinal channel, up to C3. After this contour there is a space of
2 slices without any contour. Later on, four structures of transition (2 cm of length). The upper target is calculated by means of
two double arches VMAT (160–60◦ and 300–200◦) and the following objectives: Dmax =16.5Gy, (weight = 1), uniform dose=15.50
(weight = 50)and Dmin = 15Gy (weight = 1); Dmin of T1, T2, T3 and T4 are set to 80%, 60% 40% and 20% of 15Gy. Once the upper
treatment is optimized, the spinal is planned. Two VMAT arcs of 178–115◦ and 235–182◦ are selected. The new goals are: uniform
dose 15.5Gy (weight = 50) for lower target, Dmax for lungs of 10Gy (weight = 1) and for all structures of transition uniform dose of
15Gy.
Results. The acute toxicity has been minimal, with nauseas during the ﬁrst three days of treatment, and hematologic toxicity I.
The body dose did not surpass 16.3Gy with an average dose of 4.8Gy. Maximum dose for the lungs was 11.9Gy, with an average
of 2.8Gy.
Conclusion. Our technology that overlaps VMAT’s arches is very efﬁcient and competitive procedure.
http://dx.doi.org/10.1016/j.rpor.2013.03.376
Evidence of the inﬂuence of overall treatment time delay in radiotherapy of head and neck cancer in local control
and survival. An extensive review of the literature
J. González Ferreira1, J. Jaen Olasolo1, I. Azinovic2, B. Jeremic3
1 Instituto Oncológico Cartuja (Grupo-IMO), Oncología Radioterápica, Spain
2 Director Médico del Grupo IMO, Oncología Radioterápica, Spain
3 Stellenbosch University and Tygerberg Hospital, Head, Division of Radiation Oncology, South Africa
Introduction. Treatment delays in completing radiotherapy (RT) in head and neck cancer (H&NC) is a major problem revealed by
the growing published evidence. Overall treatment time (OTT) may be a critical predictor regarding tumor control and/or survival.
Materials and methods. An extensive bibliographic search was performed looking for papers analyzing possible relationships
between OTT prolongation and loco-regional control rates (LRC) or survival (SV) in H&NC. We searched in evidence-based
databases, including MEDLINE original articles, using a broad strategy of free terms included in the Title/Abstract, such as
